RxSight Reports Q2 Sales Drop Amid Strategic Collaboration With Alcon
RxSight reported a preliminary 20% year-over-year decline in second-quarter sales to $27 million excluding collaboration revenue. The company attributed the drop to competitive launches and weaker consumer sentiment, but highlighted its strategic partnership with Alcon as a catalyst for long-term growth, raising full-year revenue guidance to between $140 million and $160 million.
Topics: Alcon collaboration Light Adjustable Lens Q2 sales decline revenue guidance RxSight